{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:07:39Z","timestamp":1770138459405,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.antiviral.2017.01.015","type":"journal-article","created":{"date-parts":[[2017,1,26]],"date-time":"2017-01-26T12:15:45Z","timestamp":1485432945000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antiviral response and resistance analysis of treatment-na\u00efve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256"],"prefix":"10.1016","volume":"140","author":[{"given":"Hongmei","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-7767","authenticated-orcid":false,"given":"Charlotte","family":"Hedskog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-6970","authenticated-orcid":false,"given":"Angela","family":"Worth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.01.015_bib1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.01.015_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-015-0412-z","article-title":"Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.antiviral.2017.01.015_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for Study of the Liver","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2017.01.015_bib4","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.01.015_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/jvh.12405","article-title":"Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy","volume":"22","author":"Hedskog","year":"2015","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2017.01.015_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.01.015_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.01.015_bib8","first-page":"1134A","article-title":"Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. EASL abstract no. 1936","volume":"60","author":"Krishnan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.01.015_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.02606-15","article-title":"Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir","volume":"60","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib10","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2017.01.015_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep.28467","article-title":"Simeprevir plus sofosbuvir (12 and 8 Weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study","volume":"64","author":"Kwo","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.01.015_bib12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.01.015_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.01.015_bib14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In\u00a0vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.01.015_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.01.015_bib18","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib19","series-title":"EASL International Liver Conference, Barcelona, Spain","article-title":"High SVR12 with 16 Weeks of Tegobuvirand GS-9256 plus peginterferon-alfa2a and ribavirinin treatment-na\u00efve genotype 1 HCV patients","author":"Nelson","year":"2012"},{"issue":"3","key":"10.1016\/j.antiviral.2017.01.015_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.01.015_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcv.2015.08.015","article-title":"Development and persistence of DAA resistance associated mutations in patients failing HCV treatment","volume":"72","author":"Paolucci","year":"2015","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2017.01.015_bib22","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.06283-11","article-title":"Pharmacokinetic\/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors","volume":"56","author":"Reddy","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2017.01.015_bib24","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bmcl.2011.12.038","article-title":"Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3\/4A protease with potent clinical activity","volume":"22","author":"Sheng","year":"2012","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2017.01.015_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.02.005","article-title":"Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort","volume":"65","author":"Shepherd","year":"2015","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2017.01.015_bib26","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"55","author":"Shih","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib27","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/JCM.00838-12","article-title":"Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy","volume":"50","author":"Svarovskaia","year":"2012","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2017.01.015_bib29","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1128\/AAC.02672-13","article-title":"Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir","volume":"58","author":"Tong","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1086\/595296","article-title":"Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1","volume":"199","author":"Underwood","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.01.015_bib31","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1128\/AAC.01444-15","article-title":"In\u00a0vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants","volume":"59","author":"Verbinnen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.01.015_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Hepatology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216304338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216304338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T05:01:08Z","timestamp":1530075668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216304338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":30,"alternative-id":["S0166354216304338"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.01.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral response and resistance analysis of treatment-na\u00efve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}